Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1987 Jun;31(6):915–919. doi: 10.1128/aac.31.6.915

Pharmacokinetics of ciprofloxacin in cystic fibrosis.

R L Davis, J R Koup, J Williams-Warren, A Weber, L Heggen, D Stempel, A L Smith
PMCID: PMC284211  PMID: 3619423

Abstract

We studied the pharmacokinetics of ciprofloxacin in 12 adult males with and 12 adult males without cystic fibrosis (CF). In a randomized crossover sequence, the subjects received 200 mg intravenously or 750 mg orally. With intravenous dosing, subjects also received 651 mg of iothalamate, a marker of glomerular filtration, and 700 mg of antipyrine, an indicator of hepatic oxidative drug metabolism. Pharmacokinetic parameters were determined by model independent methods. In the CF subjects, the ciprofloxacin concentration in serum during the first hour after intravenous administration was higher, and the oral absorption rate was slower. Other parameters did not differ between the groups. Mean concentrations in serum 5 min postinfusion were 3.08 and 2.14 micrograms/ml, and mean peak concentrations after oral dosing were 3.24 and 3.34 micrograms/ml in subjects with and without CF, respectively. Mean values for elimination half-life in all subjects were 4.8 and 5.0 h after intravenous and oral administration, respectively. The mean renal clearances in all subjects after intravenous and oral administration were 19.4 and 14.5 liters/h and accounted for 64 and 47% of the total clearance, respectively. These values were significantly greater than renal iothalamate clearance, indicating that tubular secretion contributed to the renal clearance of ciprofloxacin. A total of 69 and 35.4% of the administered ciprofloxacin was recovered from the urine within 48 h after intravenous and oral administration, respectively. The mean bioavailability was 71.2% and did not differ between the groups. We conclude that similar dosing regimens can be used to treat patients with CF and their normal counterparts.

Full text

PDF
915

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bauernfeind A., Petermüller C. In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid. Eur J Clin Microbiol. 1983 Apr;2(2):111–115. doi: 10.1007/BF02001575. [DOI] [PubMed] [Google Scholar]
  2. Bender S. W., Dalhoff A., Shah P. M., Strehl R., Posselt H. G. Ciprofloxacin pharmacokinetics in patients with cystic fibrosis. Infection. 1986 Jan-Feb;14(1):17–21. doi: 10.1007/BF01644804. [DOI] [PubMed] [Google Scholar]
  3. Bergan T., Delin C., Johansen S., Kolstad I. M., Nord C. E., Thorsteinsson S. B. Pharmacokinetics of ciprofloxacin and effect of repeated dosage on salivary and fecal microflora. Antimicrob Agents Chemother. 1986 Feb;29(2):298–302. doi: 10.1128/aac.29.2.298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Crump B., Wise R., Dent J. Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrob Agents Chemother. 1983 Nov;24(5):784–786. doi: 10.1128/aac.24.5.784. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Elwood C. M., Sigman E. M. The measurement of glomerular filtration rate and effective renal plasma flow in man by iothalamate 125-I and iodopyracet 131-I. Circulation. 1967 Sep;36(3):441–448. doi: 10.1161/01.cir.36.3.441. [DOI] [PubMed] [Google Scholar]
  6. Fass R. J. In vitro activity of ciprofloxacin (Bay o 9867). Antimicrob Agents Chemother. 1983 Oct;24(4):568–574. doi: 10.1128/aac.24.4.568. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Goldfarb J., Wormser G. P., Inchiosa M. A., Jr, Guideri G., Diaz M., Gandhi R., Goltzman C., Mascia A. V. Single-dose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis. J Clin Pharmacol. 1986 Mar;26(3):222–226. doi: 10.1002/j.1552-4604.1986.tb02938.x. [DOI] [PubMed] [Google Scholar]
  8. Gonzalez M. A., Moranchel A. H., Duran S., Pichardo A., Magana J. L., Painter B., Forrest A., Drusano G. L. Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers. Antimicrob Agents Chemother. 1985 Aug;28(2):235–239. doi: 10.1128/aac.28.2.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Höffken G., Lode H., Prinzing C., Borner K., Koeppe P. Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother. 1985 Mar;27(3):375–379. doi: 10.1128/aac.27.3.375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Joos B., Ledergerber B., Flepp M., Bettex J. D., Lüthy R., Siegenthaler W. Comparison of high-pressure liquid chromatography and bioassay for determination of ciprofloxacin in serum and urine. Antimicrob Agents Chemother. 1985 Mar;27(3):353–356. doi: 10.1128/aac.27.3.353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kelly H. W., Lovato C. Antibiotic use in cystic fibrosis. Drug Intell Clin Pharm. 1984 Oct;18(10):772–783. doi: 10.1177/106002808401801001. [DOI] [PubMed] [Google Scholar]
  12. LeBel M., Bergeron M. G., Vallée F., Fiset C., Chassé G., Bigonesse P., Rivard G. Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients. Antimicrob Agents Chemother. 1986 Aug;30(2):260–266. doi: 10.1128/aac.30.2.260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ledergerber B., Bettex J. D., Joos B., Flepp M., Lüthy R. Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. Antimicrob Agents Chemother. 1985 Mar;27(3):350–352. doi: 10.1128/aac.27.3.350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Mendelman P. M., Smith A. L., Levy J., Weber A., Ramsey B., Davis R. L. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis. 1985 Oct;132(4):761–765. doi: 10.1164/arrd.1985.132.4.761. [DOI] [PubMed] [Google Scholar]
  15. Muytjens H. L., van der Ros-van de Repe J., van Veldhuizen G. Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid. Antimicrob Agents Chemother. 1983 Aug;24(2):302–304. doi: 10.1128/aac.24.2.302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Perrier D., Mayersohn M. Noncompartmental determination of the steady-state volume of distribution for any mode of administration. J Pharm Sci. 1982 Mar;71(3):372–373. doi: 10.1002/jps.2600710332. [DOI] [PubMed] [Google Scholar]
  17. Tartaglione T. A., Raffalovich A. C., Poynor W. J., Espinel-Ingroff A., Kerkering T. M. Pharmacokinetics and tolerance of ciprofloxacin after sequential increasing oral doses. Antimicrob Agents Chemother. 1986 Jan;29(1):62–66. doi: 10.1128/aac.29.1.62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Taussig L. M., Kattwinkel J., Friedewald W. T., Di Sant'Agnese P. A. A new prognostic score and clinical evaluation system for cystic fibrosis. J Pediatr. 1973 Mar;82(3):380–390. doi: 10.1016/s0022-3476(73)80110-6. [DOI] [PubMed] [Google Scholar]
  19. Vesell E. S. The antipyrine test in clinical pharmacology: conceptions and misconceptions. Clin Pharmacol Ther. 1979 Sep;26(3):275–286. doi: 10.1002/cpt1979263275. [DOI] [PubMed] [Google Scholar]
  20. Vestal R. E., Norris A. H., Tobin J. D., Cohen B. H., Shock N. W., Andres R. Antipyrine metabolism in man: influence of age, alcohol, caffeine, and smoking. Clin Pharmacol Ther. 1975 Oct;18(4):425–432. doi: 10.1002/cpt1975184425. [DOI] [PubMed] [Google Scholar]
  21. Weber A. F., Lee D. W., Opheim K., Smith A. L. Quantitation of iothalamate in serum and urine by high-performance liquid chromatography. J Chromatogr. 1985 Feb 8;337(2):434–440. doi: 10.1016/0378-4347(85)80060-8. [DOI] [PubMed] [Google Scholar]
  22. Weber A., Chaffin D., Smith A., Opheim K. E. Quantitation of ciprofloxacin in body fluids by high-pressure liquid chromatography. Antimicrob Agents Chemother. 1985 Apr;27(4):531–534. doi: 10.1128/aac.27.4.531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Weber A., Opheim K., Smith A. L. Simplified high performance liquid chromatographic quantitation of antipyrine. J Chromatogr Sci. 1984 Jun;22(6):239–240. doi: 10.1093/chromsci/22.6.239. [DOI] [PubMed] [Google Scholar]
  24. Wingender W., Graefe K. H., Gau W., Förster D., Beermann D., Schacht P. Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers. Eur J Clin Microbiol. 1984 Aug;3(4):355–359. doi: 10.1007/BF01977494. [DOI] [PubMed] [Google Scholar]
  25. Wise R., Andrews J. M., Edwards L. J. In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother. 1983 Apr;23(4):559–564. doi: 10.1128/aac.23.4.559. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Wise R., Lockley R. M., Webberly M., Dent J. Pharmacokinetics of intravenously administered ciprofloxacin. Antimicrob Agents Chemother. 1984 Aug;26(2):208–210. doi: 10.1128/aac.26.2.208. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES